Loading
INBRAIN Neuroelectronics
INBRAIN builds ultra-thin graphene neural interfaces that record and modulate brain activity in both directions. Machine learning drives the decoding and therapy. The platform targets neurological conditions such as Parkinson's disease, epilepsy and stroke, and is aimed at patients and clinicians. It is an investigational device in clinical trials, including a first-in-human study that reported interim results in 2025. The company is a venture-funded medtech spin-off from the Graphene Flagship and ICN2/ICREA. It closed a $50M Series B led by imec.xpand in October 2024, bringing total funding to about $68M. Merck KGaA is a development partner, and imec is a manufacturing-scale-up partner.
Funding
Every round, secondary, debt facility or acquisition involving INBRAIN Neuroelectronics that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—